Your browser doesn't support javascript.
loading
Distinct contributions of partial and full EMT to breast cancer malignancy.
Lüönd, Fabiana; Sugiyama, Nami; Bill, Ruben; Bornes, Laura; Hager, Carolina; Tang, Fengyuan; Santacroce, Natascha; Beisel, Christian; Ivanek, Robert; Bürglin, Thomas; Tiede, Stefanie; van Rheenen, Jacco; Christofori, Gerhard.
Affiliation
  • Lüönd F; Department of Biomedicine, University of Basel, 4058 Basel, Switzerland.
  • Sugiyama N; Department of Biomedicine, University of Basel, 4058 Basel, Switzerland. Electronic address: nami.matsuda@unibas.ch.
  • Bill R; Department of Biomedicine, University of Basel, 4058 Basel, Switzerland.
  • Bornes L; Division of Molecular Pathology, Oncode Institute, Netherlands Cancer Institute, 1006 BE Amsterdam, the Netherlands.
  • Hager C; Department of Biomedicine, University of Basel, 4058 Basel, Switzerland.
  • Tang F; Department of Biomedicine, University of Basel, 4058 Basel, Switzerland.
  • Santacroce N; Department of Biosystems Science and Engineering, ETH Zürich, 4058 Basel, Switzerland.
  • Beisel C; Department of Biosystems Science and Engineering, ETH Zürich, 4058 Basel, Switzerland.
  • Ivanek R; Department of Biomedicine, University of Basel, 4058 Basel, Switzerland.
  • Bürglin T; Department of Biomedicine, University of Basel, 4058 Basel, Switzerland.
  • Tiede S; Department of Biomedicine, University of Basel, 4058 Basel, Switzerland.
  • van Rheenen J; Division of Molecular Pathology, Oncode Institute, Netherlands Cancer Institute, 1006 BE Amsterdam, the Netherlands.
  • Christofori G; Department of Biomedicine, University of Basel, 4058 Basel, Switzerland. Electronic address: gerhard.christofori@unibas.ch.
Dev Cell ; 56(23): 3203-3221.e11, 2021 12 06.
Article de En | MEDLINE | ID: mdl-34847378
ABSTRACT
Epithelial-mesenchymal transition (EMT) is a transient, reversible process of cell de-differentiation where cancer cells transit between various stages of an EMT continuum, including epithelial, partial EMT, and mesenchymal cell states. We have employed Tamoxifen-inducible dual recombinase lineage tracing systems combined with live imaging and 5-cell RNA sequencing to track cancer cells undergoing partial or full EMT in the MMTV-PyMT mouse model of metastatic breast cancer. In primary tumors, cancer cells infrequently undergo EMT and mostly transition between epithelial and partial EMT states but rarely reach full EMT. Cells undergoing partial EMT contribute to lung metastasis and chemoresistance, whereas full EMT cells mostly retain a mesenchymal phenotype and fail to colonize the lungs. However, full EMT cancer cells are enriched in recurrent tumors upon chemotherapy. Hence, cancer cells in various stages of the EMT continuum differentially contribute to hallmarks of breast cancer malignancy, such as tumor invasion, metastasis, and chemoresistance.
Sujet(s)
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Tumeurs du sein / Marqueurs biologiques tumoraux / Régulation de l'expression des gènes tumoraux / Résistance aux médicaments antinéoplasiques / Transition épithélio-mésenchymateuse / Tumeurs du poumon Limites: Animals / Female / Humans Langue: En Journal: Dev Cell Sujet du journal: EMBRIOLOGIA Année: 2021 Type de document: Article Pays d'affiliation: Suisse

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Tumeurs du sein / Marqueurs biologiques tumoraux / Régulation de l'expression des gènes tumoraux / Résistance aux médicaments antinéoplasiques / Transition épithélio-mésenchymateuse / Tumeurs du poumon Limites: Animals / Female / Humans Langue: En Journal: Dev Cell Sujet du journal: EMBRIOLOGIA Année: 2021 Type de document: Article Pays d'affiliation: Suisse